Name: RMC-6236 Cat#: EX-A6631

Target:: Ras
Pathway: GPCR/G Protein; MAPK/ERK Pathway

Chemical Structure:



Chemical Name	(1S,2S)-N-((63S,4S,Z)-11-ethyl-12-(2-((S)-1-methoxyethyl)-5-(4-methylpiperazin-1-yl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-61,62,63,64,65,66-hexahydro-11H-8-oxa-2(4,2)-thiazola-1(5,3)-indola-6(1,3)-pyridazinacycloundecaphane-4-yl)-2-methylcyclopropane-1-carboxamide

Molecular Weight	811.047	Storage	3 years -20°C powder 6 months -80°C in solvent Away from light
Formula	C44H58N8O5S		
CAS No.	2765081-21-6	Synonyms	RMC 6236; RMC6236

Solubility (25°C) *	In vitro	DMSO	Soluble, >100mg/mL (Need ultrasonic)
		Ethanol	N/A
		Water	N/A
	In vivo （should be freshly prepared each time）		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	1.2330 mL	6.1649 mL	12.3297 mL
5 mM	0.2466 mL	1.2330 mL	2.4659 mL
10 mM	0.1233 mL	0.6165 mL	1.2330 mL

*The above data is based on the product molecular weight 811.047.

Biological Activities:

Description	RMC-6236 is a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS^{MULTI}(ON) inhibitor.
IC_{50} & Targe	KRas G12D
In Vitro	RMC-6236 (Compound A122) (5 days) inhibits cell viability with an IC50 of 1-10 μM against AsPC-1 (K-Ras G12D).

References	[1]. Gustafson, W. Clay et al. Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS^{MULTI}(ON) inhibitor. Journal of Clinical Oncology 2022 40:4_suppl, 591-591. [2]. Ethan AHLER, et al. Use of sos1 inhibitors to treat malignancies with shp2 mutations. Patent WO2022060583A1.